Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Go back to Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 33.43 -0.43 (1.27%)
Previous Close $33.86    52 Week High $5.17 
Open $33.86    52 Week Low $0.94 
Day High $34.01    P/E N/A 
Day Low $32.84    EPS $0.00 
Volume 2,890,542